ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Atherosclerosis"

  • Abstract Number: 825 • 2015 ACR/ARHP Annual Meeting

    Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis

    Gulsen Ozen1, Fatmanur Korkmaz2, Murat Sunbul3, Rabia Deniz4, Kursat Tigen3, Pamir Atagunduz1, Nevsun Inanc1 and Haner Direskeneli1, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Marmara University Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: During the last decade, it has been shown that cardiovascular disease (CVD) in systemic sclerosis (SSc) is increased and accounts for ~30% of the…
  • Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting

    Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus

    Simantini Sakhardande1, Monica Purmalek1, Maureen Sampson2, Yenealem Temesgen-Oyelakim3, Alice Fike4, Taufiq Salahuddin5, Balaji Natarajan5, Zerai Manna6, Elizabeth Joyal6, Marcus Chen5, Sarfaraz Hasni6, Nehal N. Mehta5,7, Alan Remaley5 and Mariana J. Kaplan1, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2CC/NIH, Bethesda, MD, 3Office of the Clinical Director,National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5NHLBI, National Institutes of Health, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 7National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD

    Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…
  • Abstract Number: 2637 • 2014 ACR/ARHP Annual Meeting

    Assessment of Plaque Thickness and Area in Patients with SLE As Measures of Atherosclerosis – Associations with Disease Activity

    Sara Croca1, Maura Griffin2, David Isenberg3, Andrew Nicolaides4 and Anisur Rahman5, 15 University Street, University College London, London, United Kingdom, 2Vascular Screening and Diagnostic Centre, London, United Kingdom, 3Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 4St Georges London/Nicosia Medical School, University of Nicosia, Cyprus, Nicosia, Cyprus, 5Centre for Rheumatology Research, University College London, London, United Kingdom

    Background/Purpose SLE is an independent risk factor for cardiovascular disease (CVD). Traditional risk stratification tools underestimate CVD risk in patients with SLE. Previous vascular ultrasound…
  • Abstract Number: 628 • 2014 ACR/ARHP Annual Meeting

    The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease

    Lihi Eder1, Fatima Abji1, Cheryl Rosen2, Vinod Chandran1 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose The pathophysiologic mechanisms underlying the accelerated atherosclerosis in patients with psoriatic disease (PsD) are unknown. We aimed to investigate candidate pathways involved in this…
  • Abstract Number: 2617 • 2014 ACR/ARHP Annual Meeting

    No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study

    Aikaterini I. Arida1, Maria Konsta1, Alexios Iliopoulos2, Maria Tektonidou3, George Konstantonis1, George D. Kitas4, Athanasios D. Protogerou1 and Petros P. Sfikakis1, 1First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 2Department of Rheumatology, Veterans Administration Hospital, Athens, Greece, 3First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Chronic inflammatory arthritis is associated with increased cardiovascular disease (CVD) risk. The mechanisms behind this link include chronic inflammation, comorbidities and disease-related drugs. CV…
  • Abstract Number: 627 • 2014 ACR/ARHP Annual Meeting

    HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease

    Lihi Eder1, Fatima Abji1, Cheryl Rosen2, Vinod Chandran1 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose Recent evidence supports the link between the extent of inflammation and cardiovascular risk in patients with psoriatic disease (PsD). We aimed to investigate the…
  • Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting

    Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

    Raquel López-Mejías1, Fernanda Genre1, Mercedes García-Bermúdez2, Alfonso Corrales1, Carlos González-Juanatey3, Begoña Ubilla1, J. Llorca4, Encarnación Amigo5, Jose A. Miranda-Filloy6, Trinitario Pina Murcia1, Ricardo Blanco7, Santos Castañeda8, Javier Martin9 and Miguel A González-Gay1, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 5Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, 6Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 7Hospital Marques de Valdecilla, Santander, Spain, 8Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 9Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…
  • Abstract Number: 542 • 2014 ACR/ARHP Annual Meeting

    Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis – a Cohort Study

    Lihi Eder1, Arane Thavaneswaran1, Vinod Chandran1, Hua Shen2, Richard J. Cook2 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose The prevalence of cardiovascular (CV) morbidity is increased in patients with psoriatic arthritis (PsA). CV risk is only partially explained by traditional CV risk…
  • Abstract Number: 1978 • 2014 ACR/ARHP Annual Meeting

    Role of Monocytes Subsets in the Pathology of Rheumatoid Arthritis: Involvement in Endothelial Dysfunction and Proinflammatory Profile

    Chary Lopez-Pedrera, Patricia Ruiz-Limon, Carlos Perez-Sanchez, Rosario Carretero, Yolanda Jiménez Gómez, Ángeles Aguirre Zamorano, Jerusalem calvo-Gutierrez, Eduardo Collantes-Estevez, Alejandro Escudero-Contreras and Nuria Barbarroja, Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain

    Background/Purpose Different frequency of monocytes subsets has been reported in rheumatoid arthritis (RA).Human monocytes are divided into three main subpopulations according to expression of the…
  • Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting

    Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases

    Eirik Ikdahl1, Silvia Rollefstad1, Jonny Hisdal2, Inge C. Olsen3, Ingar Holme4, Terje R. Pedersen5, Tore Kvien6 and Anne Grete Semb1, 1Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, 5Faculty of Medicine, University of Oslo, Oslo, Norway, 6Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…
  • Abstract Number: 1913 • 2014 ACR/ARHP Annual Meeting

    Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases

    Silvia Rollefstad1, Eirik Ikdahl1, Jonny Hisdal2, Inge C. Olsen3, Ingar Holme4, Hilde Berner Hammer5, Knut T. Smerud6, G Kitas7, Terje R. Pedersen8, Tore K. Kvien9 and Anne Grete Semb1, 1Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, 5Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, 6Smerud Medical Research International AS, Oslo, Norway, 7The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, 8Faculty of Medicine, University of Oslo, Oslo, Norway, 9PsAID taskforce, EULAR, Zurich, Switzerland

    Background/Purpose Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol…
  • Abstract Number: 438 • 2014 ACR/ARHP Annual Meeting

    Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease

    Tsuyoshi Shirai1, Eric L. Matteson2, David G. Harrison3, Barbara B. Wallis4, Themistocles L. Assimes5, Jorg J. Goronzy6 and Cornelia M. Weyand1, 1Medicine, Stanford University School of Medicine, Stanford, CA, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 4Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, 5Stanford University School of Medicine, Stanford, CA, 6Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Patients with RA have an increased risk of developing coronary artery disease (CAD) compared to the general population. The underlying pathological process of CAD…
  • Abstract Number: 1633 • 2014 ACR/ARHP Annual Meeting

    Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients

    Susan Kay1, Niels Heegaard2 and Anne Voss3, 1Rheumatolog, Rheumatology, Odense, Denmark, 2Cinical Biochemistry and Pharmacology, Cinical Biochemistry and Pharmacology, Odense, Denmark, 3Reumatology, Reumatology, Odense, Denmark

    Background/Purpose . Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which may be due to an increased prevalence of atherosclerosis.…
  • Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting

    Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)

    Ivana Hollan1, Gunnbjørg Hjeltnes2, Torstein Lyberg3, Stefan Agewall3, Allan Wiik4, Knut Mikkelsen5, Øystein T. Førre6, Tram T. Vuong3 and Svein O. Kolset3, 1Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 2Medicine, Innlandet Hospital Trust, Lillehammer, Norway, 3University of Oslo, Oslo, Norway, 4Clinical Biochem/Immunology, Statens Serum Institute, Copenhagen S, Denmark, 5Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 6Oslo University Hospital, Oslo, Norway

    Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…
  • Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting

    Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis

    M. Elaine Husni1, Danielle Brennan2, WH Wilson Tang3 and Stanley Hazen3, 1Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 3Cardiology, CCF, Cleveland, OH

    Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity.  Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology